ImmunityBio (IBRX) stock surged over 30% on Thursday after the company released preliminary 2025 results, which pointed to a 700% jump in Anktiva sales. The biotechnology company reported about $113 million in net product revenue for 2025, up from just $15 million the year before, driven by rising adoption of the therapy.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Preliminary fourth quarter 2025 revenue alone reached $38.3 million, up 20% from the previous quarter and 431% higher than the same period in 2024.
Global Approvals Add Fuel to the Rally
Beyond sales growth, ImmunityBio also announced several major regulatory wins that expand Anktiva’s reach. These include:
- Saudi FDA approval for Anktiva in combination with checkpoint inhibitors for metastatic non‑small cell lung cancer, the first global approval for this indication.
- Additional Saudi approval for Anktiva plus BCG in BCG‑unresponsive bladder cancer, adding to existing approvals in the U.S., U.K., and conditional approval in the EU.
- Earlier in the week, the company also released positive lung cancer data, further expanding the drug’s potential market.
These milestones signal rising global confidence in the therapy and create opportunities for new revenue streams.
Here’s Why Anktiva Is Driving Strong Growth
Anktiva is an IL‑15-based therapy designed to activate T cells and natural killer cells. It has delivered strong results in bladder cancer, with high response rates and long-lasting benefits. Demand has grown quickly, with unit sales up 750% in 2025 compared to 2024.
The company is also progressing ahead of schedule in its Phase 2b trial for first‑line, BCG‑naïve bladder cancer, with full enrollment expected in the first half of 2026.
Overall, the explosive sales growth, new global approvals, and strong clinical results have positioned ImmunityBio as one of the standout biotech movers of early 2026. While the IBRX stock is still volatile, as most commercial‑stage biotechs are, the momentum behind Anktiva is clearly picking up.
Is ImmunityBio a Good Stock to Buy?
Turning to Wall Street, analysts have a Strong Buy consensus rating on IBRX stock based on three Buys assigned in the past three months. Further, the average ImmunityBio price target of $7.33 per share implies 85.57% upside potential.
